Monte Rosa Therapeutics, Inc.
GLUE
$4.59
-$0.23-4.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 59.44% | 246.66% | 140.41% | 31.60% | 13.84% |
| Total Depreciation and Amortization | 19.55% | -1.82% | 31.60% | 15.81% | 8.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.57% | -9.84% | 1.11% | -25.30% | 58.66% |
| Change in Net Operating Assets | -881.44% | -664.73% | 90.03% | -155.59% | -150.89% |
| Cash from Operations | -25.04% | -19.20% | 335.05% | 15.02% | -9.65% |
| Capital Expenditure | 16.17% | -14.67% | 89.17% | 75.95% | 68.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 145.69% | -977.83% | -292.12% | 2.31% | -336.54% |
| Cash from Investing | 141.41% | -1,117.24% | -316.10% | 5.95% | -429.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.29% | -94.31% | 1,148.44% | -98.64% | 4,205.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -112.06% | -- | -- |
| Cash from Financing | -99.63% | -94.31% | -97.58% | -98.64% | 8,068.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -199.26% | -419.16% | 42.73% | 39.48% | 263.22% |